Somnomed Limited (AU:SOM)
ASX:SOM
Want to see AU:SOM full AI Analyst Report?
SOM Stock Chart & Stats
AU$0.56
AU$0.03(6.67%)
At close: 4:00 PM EST
AU$0.56
AU$0.03(6.67%)
Day’s Range― - ―
52-Week RangeAU$0.44 - AU$0.95
Previous CloseN/A
Volume51.81K
Average Volume (3M)705.41K
Market Cap
AU$124.88M
Enterprise ValueAU$129.62M
Total Cash (Recent Filing)AU$18.03M
Total Debt (Recent Filing)AU$14.01M
Price to Earnings (P/E)52.9
Beta1.21
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding219,083,250
10 Day Avg. Volume159,446
30 Day Avg. Volume705,406
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)2.97
Price to Sales (P/S)1.24
P/FCF Ratio25.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.00Price Target Upside77.68% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth TrendConsistent mid-teens revenue growth demonstrates expanding adoption of SomnoMed’s mandibular advancement splints across markets. Durable top-line expansion supports scale economics, broader provider penetration, and the ability to invest in distribution and product improvements over the next 2–6 months.
Strong Gross MarginsSustained ~60% gross margins indicate favorable product economics and pricing power for custom oral appliances. High manufacturing margins create a structural buffer versus cost inflation and allow reinvestment into R&D, sales incentives and channel support, aiding longer-term margin recovery.
Improved Cash GenerationSharp free cash flow improvement and positive operating cash flow despite accounting losses show strong cash conversion and working-capital management. This provides a durable liquidity cushion, reduces near-term refinancing risk, and funds strategic initiatives without immediate equity dilution.
Bears Say
Persistent Net LossesOngoing negative net and EBIT margins indicate the business has not yet converted revenue growth into consistent operating profitability. Without margin recovery, the firm may need continued external funding or slower reinvestment, limiting ability to compound returns for shareholders.
Negative Return On EquityA negative ROE signals the company is not generating returns from invested capital, undermining shareholder value creation. Persisting negative ROE can constrain investor confidence and raise pressure on management to improve operational efficiency or alter capital allocation.
Predominantly Transactional Revenue ModelA per-device sales model yields limited recurring revenue and depends on continuous patient acquisition and provider throughput. Given device longevity, this structural cadence can slow predictable revenue growth and requires sustained marketing and channel effort to scale durable revenue streams.
Somnomed Limited News
SOM FAQ
What was Somnomed Limited’s price range in the past 12 months?
Somnomed Limited lowest share price was AU$0.44 and its highest was AU$0.94 in the past 12 months.
What is Somnomed Limited’s market cap?
Somnomed Limited’s market cap is AU$124.88M.
When is Somnomed Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Somnomed Limited’s earnings last quarter?
Currently, no data Available
Is Somnomed Limited overvalued?
According to Wall Street analysts Somnomed Limited’s price is currently Undervalued.
Does Somnomed Limited pay dividends?
Somnomed Limited does not currently pay dividends.
What is Somnomed Limited’s EPS estimate?
Somnomed Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Somnomed Limited have?
Somnomed Limited has 219,083,250 shares outstanding.
What happened to Somnomed Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Somnomed Limited?
Currently, no hedge funds are holding shares in AU:SOM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Somnomed Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$1.00 (77.68% Upside)
AU$1.00 (77.68% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
41.28%
12-Months-Change
Fundamentals
Return on Equity
-5.31%
Trailing 12-Months
Asset Growth
14.75%
Trailing 12-Months
Company Description
Somnomed Limited
SomnoMed Limited, together with its subsidiaries, engages in the production and sale of devices for the oral treatment of sleep related disorders in Europe, North America, and the Asia Pacific region. It offers SomnoDent, an oral appliance for obstructive sleep apnea; SomnoBrux, a dental guard for the treatment of teeth grinding damage; SomMorning Repositioner, which help return mandible back to its pre-treatment centric position; and SomTabs for cleaning oral devices. The company was incorporated in 1987 and is headquartered in Crows Nest, Australia.
SOM Company Deck
SOM Earnings Call
Q2 2026
0:00 / 0:00
SOM Stock 12 Month Forecast
Average Price Target
AU$1.00
▲(77.68% Upside)
Technical Analysis
Options Prices
Currently, No data available
---